Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study

Weijun Fu, Soo‐Mee Bang, Honghui Huang, Kihyun Kım, Wei Li, Gang An, Je‐Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Tung-Liang Lin, Chor Sang Chim, Ming Qi, Jianping Wang, Xiaolin Lü, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Tianyuan Zhou, Lu Yin, Yunan Li, Renyi Zhang, Jian Hou, Jianxiang WangClinical 2023 · DOI

Abstract

gov as #NCT03217812.
BibTeX
@inproceedings{fu2023bortezomib,
  author = {Weijun Fu and Soo‐Mee Bang and Honghui Huang and Kihyun Kım and Wei Li and Gang An and Je‐Jung Lee and Zhen Cai and Jie Jin and Yafei Wang and Tung-Liang Lin and Chor Sang Chim and Ming Qi and Jianping Wang and Xiaolin Lü and Yang Song and Bin Jia and Xue Yang and Wenyu Liu and Tianyuan Zhou and Lu Yin and Yunan Li and Renyi Zhang and Jian Hou and Jianxiang Wang},
  title = {{Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1016/j.clml.2023.02.009},
}

Loading related content...

Figure